Nuvectis Pharma
NVCT
33 hedge funds and large institutions have $16.5M invested in Nuvectis Pharma in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 5 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0.41% less ownership
Funds ownership: 7.83% → 7.41% (-0.41%)
11% less funds holding
Funds holding: 37 → 33 (-4)
18% less capital invested
Capital invested by funds: $20M → $16.5M (-$3.57M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$651K |
| 2 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$381K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$365K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$248K |
| 5 |
MWM
Moran Wealth Management
Naples,
Florida
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMFC
J.M. Forbes & Co
Boston,
Massachusetts
|
-$478K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$448K |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$364K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$200K |
| 5 |
Renaissance Technologies
New York
|
-$159K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $17.9K | +$261 | +18 | +1% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $14K | -$23.2K | -1,604 | -60% |
|
|
AB
28
Amalgamated Bank
New York
| $13K | – | – | – |
|
29
Legal & General Group
London,
United Kingdom
| $10.8K | – | – | – |
|
|
AIP
30
Ameritas Investment Partners
Lincoln,
Nebraska
| $7.3K | – | – | – |
|
|
HCM
31
Hollencrest Capital Management
Newport Beach,
California
| $3.61K | -$40K | -2,760 | -91% |
|
32
Fidelity Investments
Boston,
Massachusetts
| $90 | -$246 | -17 | -71% |
|
33
Citigroup
New York
| $65 | -$29.5K | -2,034 | -100% |
|
|
34
Citadel Advisors
Miami,
Florida
| – | -$448K | -28,028 | Closed |
|
|
EDRH
35
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$364K | -22,820 | Closed |
|
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$200K | -11,012 | Closed |
|
|
MIM
37
MetLife Investment Management
Whippany,
New Jersey
| – | -$63.4K | -3,970 | Closed |
|
|
MLICM
38
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.56K | -411 | Closed |
|
NVCT Hedge Fund Activity: Q3 2023 in Review
33 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2023, worth a combined $16.5M — down 18% from $20M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NVCT and 1 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was BlackRock, adding an estimated $651K. The largest seller was J.M. Forbes & Co, cutting an estimated $478K.
- 33 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2023, down from 37 in Q2 2023.
- Funds reported $16.5M of Nuvectis Pharma stock for Q3 2023, down 18% quarter-over-quarter.
- 1 fund opened new Nuvectis Pharma positions in Q3 2023 and 5 closed out, a net change of -4 holders.
- The largest Nuvectis Pharma buyer in Q3 2023 was BlackRock, an estimated $651K added.
- The largest Nuvectis Pharma seller in Q3 2023 was J.M. Forbes & Co, an estimated $478K sold.
Based on aggregated 13F filings for Q3 2023.